Search

Your search keyword '"OVERALL survival"' showing total 1 results

Refine your results

1 results on '"OVERALL survival"'

1. Survival Outcomes and PROs Favor Cemiplimab + Chemotherapy vs Chemotherapy Alone in Advanced NSCLC Regardless of PD-L1 Status.

Author

Joszt, Laura

Subjects
*THERAPEUTIC use of monoclonal antibodies, *THERAPEUTIC use of antineoplastic agents, *LUNG cancer, *DISEASE progression, *EVALUATION of human services programs, *COMBINATION drug therapy, *EPIDERMAL growth factor receptors, *LUNG tumors, *CHEMORADIOTHERAPY, *MEDICAL care research, *TUMOR classification, *TREATMENT effectiveness, *CANCER patients, *ANAPLASTIC lymphoma kinase, *SURVIVAL analysis (Biometry), *QUALITY of life, *PROGRESSION-free survival, *IMMUNOTHERAPY, *PATIENT safety, *OVERALL survival, *CHEMICAL inhibitors
Abstract

The article reports on the results of the 3 EMPOWER-Lung 3 study that were presented at the 2023 European Society for Medical Oncology Congress, showing that cemiplimab plus chemotherapy showed better favorable survival benefits and patient-reported outcomes (PRO) in patients with advanced non-small cell lung cancer (NSCLC). Also cited are the median overall survival (OS), objective response rate (ORR), and progression-free survival (PFS) study results.

Published
2023

Catalog

Books, media, physical & digital resources
See catalog results